Prime Medicine
NASDAQ: PRME
Pioneering gene-editing solutions using precision genome engineering technologies.
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
2019
Pioneering gene-editing solutions using precision genome engineering technologies.
Prime Medicine (NASDAQ: PRME) is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly “search and replace” to restore normal genetic function and address the fundamental causes of disease. Prime Medicine envisions a world where Prime Editing can cure or halt disease and provide lifelong benefit to patients—shaping the future of gene editing.
“F-Prime was with us from the beginning and shared our vision for the promise of Prime’s technology. Together we can deliver hope to patients and families suffering from incurable genetic diseases.”
Keith Gottesdiener, President & CEO
